Dnaprint Genomics Stock Market Outlook
| DNAG Stock | USD 0.00001 0.00 0.00% |
Roughly 55% of DNAPrint Genomics' stockholders are presently thinking to get in. The analysis of the overall investor sentiment regarding DNAPrint Genomics suggests that some traders are interested. The current market sentiment, together with DNAPrint Genomics' historical and current headlines, can help investors time the market. In addition, many technical investors use DNAPrint Genomics stock news signals to limit their universe of possible portfolio assets.
Comfort Level 55
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use DNAPrint Genomics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward DNAPrint Genomics.
News SentimentNeutral | Hype SentimentBullish | Insider SentimentWaiting |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding DNAPrint Genomics is 'Strong Sell'. Macroaxis provides DNAPrint Genomics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding DNAG positions.
Execute DNAPrint Genomics Advice
The DNAPrint recommendation should be used to complement the investment advice compiled from the current analysts' consensus on DNAPrint Genomics. Macroaxis does not own or have any residual interests in DNAPrint Genomics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute DNAPrint Genomics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
For the selected time horizon DNAPrint Genomics has a Return On Asset of -1.05, Profit Margin of (2.36) %, Operating Margin of (7.31) %, Current Valuation of 5.64 M, Shares Owned By Institutions of 0.18 % and Price To Sales of 0.20 XWe provide trade recommendation to complement the latest expert consensus on DNAPrint Genomics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available right now. To make sure DNAPrint Genomics is not overpriced, please confirm all DNAPrint Genomics fundamentals, including its current valuation, net income, number of employees, as well as the relationship between the revenue and current ratio . As DNAPrint Genomics appears to be a penny stock we also advise to verify its revenue numbers.
DNAPrint Genomics Trading Alerts and Improvement Suggestions
| DNAPrint Genomics is way too risky over 90 days horizon | |
| DNAPrint Genomics has some characteristics of a very speculative penny stock | |
| DNAPrint Genomics appears to be risky and price may revert if volatility continues | |
| DNAPrint Genomics has high likelihood to experience some financial distress in the next 2 years | |
| DNAPrint Genomics currently holds 240 K in liabilities. DNAPrint Genomics has a current ratio of 0.17, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about DNAPrint Genomics' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 2.43 M. Net Loss for the year was (12.35 M) with profit before overhead, payroll, taxes, and interest of 446.37 K. | |
| DNAPrint Genomics currently holds about 134.35 K in cash with (5.78 M) of positive cash flow from operations. | |
| DNAPrint Genomics has a frail financial position based on the latest SEC disclosures |
DNAPrint Genomics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to DNAPrint Genomics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that DNAPrint Genomics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a DNAPrint stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 129.10 | |
Ir | Information ratio | 0.00 |
DNAPrint Genomics Volatility Alert
At this time DNAPrint Genomics exhibits very low volatility. DNAPrint Genomics appears to be a penny stock. Although DNAPrint Genomics may be, in fact, a solid short-term or long term investment, many penny stocks are speculative investment instruments that are often subject to artificial stock promotion and campaigns of hype which may lead to misinformation and misrepresentation. Please make sure you fully understand upside potential and downside risks of investing in DNAPrint Genomics or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswing without any event/news,and sudden news releases. We also encourage traders to check biographies and work history of company President, CEO or other officers before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on DNAPrint instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.DNAPrint Genomics Fundamentals Vs Peers
Comparing DNAPrint Genomics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze DNAPrint Genomics' direct or indirect competition across all of the common fundamentals between DNAPrint Genomics and the related equities. This way, we can detect undervalued stocks with similar characteristics as DNAPrint Genomics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of DNAPrint Genomics' fundamental indicators could also be used in its relative valuation, which is a method of valuing DNAPrint Genomics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare DNAPrint Genomics to competition |
| Fundamentals | DNAPrint Genomics | Peer Average |
| Return On Asset | -1.05 | -0.14 |
| Profit Margin | (2.36) % | (1.27) % |
| Operating Margin | (7.31) % | (5.51) % |
| Current Valuation | 5.64 M | 16.62 B |
| Shares Owned By Institutions | 0.18 % | 39.21 % |
| Price To Sales | 0.20 X | 11.42 X |
| Revenue | 2.43 M | 9.43 B |
| Gross Profit | 446.37 K | 27.38 B |
| EBITDA | (5.78 M) | 3.9 B |
| Net Income | (12.35 M) | 570.98 M |
| Cash And Equivalents | 134.35 K | 2.7 B |
| Total Debt | 240 K | 5.32 B |
| Current Ratio | 0.17 X | 2.16 X |
| Book Value Per Share | (0.01) X | 1.93 K |
| Cash Flow From Operations | (5.78 M) | 971.22 M |
| Number Of Employees | 24 | 18.84 K |
| Beta | 86.78 | -0.15 |
| Market Capitalization | 386.76 K | 19.03 B |
| Total Asset | 10.27 M | 29.47 B |
| Retained Earnings | (45.53 M) | 9.33 B |
| Working Capital | (9.35 M) | 1.48 B |
| Current Asset | 1.89 M | 9.34 B |
| Current Liabilities | 11.24 M | 7.9 B |
| Net Asset | 10.27 M |
DNAPrint Genomics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as DNAPrint . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 9223372 T |
About DNAPrint Genomics Buy or Sell Advice
When is the right time to buy or sell DNAPrint Genomics? Buying financial instruments such as DNAPrint Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having DNAPrint Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Cap ETFs Thematic Idea Now
Small Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small Cap ETFs theme has 187 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out DNAPrint Genomics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Can Biotechnology industry sustain growth momentum? Does DNAPrint have expansion opportunities? Factors like these will boost the valuation of DNAPrint Genomics. Projected growth potential of DNAPrint fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating DNAPrint Genomics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of DNAPrint Genomics is measured differently than its book value, which is the value of DNAPrint that is recorded on the company's balance sheet. Investors also form their own opinion of DNAPrint Genomics' value that differs from its market value or its book value, called intrinsic value, which is DNAPrint Genomics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because DNAPrint Genomics' market value can be influenced by many factors that don't directly affect DNAPrint Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between DNAPrint Genomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DNAPrint Genomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DNAPrint Genomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.